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ABSTRACT
Alternative splicing of a single pre-mRNA transcript
can produce protein isoforms that promote either
cell growth or death. Here we show that Ro-31-
8220 (Ro), an apoptotic agent that inhibits protein
kinase C and activates the c-Jun N terminal kinase,
decreased the proportion of the cell growth-promot-
ing Bcl-xL splice variant. Targeted mutagenesis
analyses narrowed down a critical sequence to a
16-nt G-tract element (Gt16). Transferring this ele-
ment to a heterologous gene conferred Ro response
on an otherwise constitutive exon. The Ro effect was
reduced by okadaic acid, an inhibitor of protein
phosphatases PP1 and PP2A, in a concentration-
dependent manner. Search in the human genome
followed by RT–PCR identified a group of genes that
contain similar exonic G-tract elements and are
responsive to Ro. Moreover, the Gt16 element also
mediates the regulation of alternative splicing by
other cell apoptosis-inducers particularly retinoic
acid. Therefore, the G-tract element likely plays a
role in the apoptotic agents-induced alternative
splicing of a group of genes. The functions of these
genes imply that this regulation will have impact on
cell growth/death.
INTRODUCTION
Alternative splicing allows the generation of more than
one protein isoforms from a single pre-mRNA transcript,
contributing greatly to the proteomic diversity (1–4). By
this way, a number of genes involved in cell growth/death
generate protein isoforms that promote either cell growth
or death (5,6). This regulation can be dynamically con-
trolled by extracellular factors but rarely has a factor been
coupled with a regulatory pre-mRNA element.
Alternative splicing of mammalian genes is controlled
by multiple cis-acting pre-mRNA elements in either
introns or exons that promote or inhibit exon inclusion
(3,7). These elements control the assembly of constitutive
splicing components mostly by binding trans-acting
factors, including the arginine/serine-rich SR proteins
(8–10), heterogeneous nuclear ribonucleoprotein particle
(hnRNP) proteins and others (3,11–15). The balance
between the positive and negative elements/factors con-
trols the inclusion of exons in speciﬁc cells or during
developmental stages. This balance can be changed by
extracellular factors but the underlying molecular basis is
less well understood than that of cell type- or develop-
mental stage-speciﬁc splicing.
Many extracellular factors, including hormones, neuro-
transmitters and pharmacological agents, can regulate
alternative splicing through protein kinases or phospha-
tases (16–18). In some cases, pre-mRNA elements and the
bound splicing factors responsive to the stimuli are
identiﬁed, facilitating the delineation of the involved
signaling pathways. For example, in the CD44 gene, the
pre-mRNA sequence for TPA (12-O-tetradecanoylphor-
bol 13-acetate) regulation of exon 5 is an A-rich element
(19–21). This element is bound by Sam68, which is directly
phosphorylated by the ERK kinase upon TPA stimulation
to enhance the inclusion of exon 5 (21).
Ro-31-8220 (Ro) is a synthetic compound originally
used as a PKC-inhibitor (22,23). It also activates the c-Jun
N-terminal kinase (JNK) and inhibits expression of the
MAP kinase phosphatase 1 MPK1 (24). It induces cell
apoptosis through PKC or other pathways (25,26). The
eﬀect of Ro on alternative splicing of genes in cell growth/
death has not been examined.
Bcl-x, a Bcl-2 family member critical for cell survival/
apoptosis (27), generates two antagonistic isoforms Bcl-xL
and Bcl-xS, through alternative inclusion of a 189-nt
fragment that encodes 63 amino acids in a region highly
conserved in the Bcl-2 family proteins (28,29). Bcl-xL
protects cells from death (27,29–33), while as Bcl-xS
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variants are diﬀerentially expressed among tissues, during
development and in diseases (29,34,35). The growth-
promoting Bcl-xL variant is increased in tumors (35). In
cultured cells, Bcl-x splicing can be regulated by ceramide,
TPA or staurosporine (36–38). Due to the two variants’
antagonistic roles in cell growth/death, attempts have been
made to induce cancer cell death or sensitivity to chemo-
therapeutic agents through modulating Bcl-x splicing
(32,39,40).
Several studies have examined the molecular compo-
nents controlling Bcl-x splicing. A 30-nt fragment contain-
ing G-tracts in the pre-mRNA reduces the Bcl-xL product
through the hnRNP H/F proteins (41). A 361-nt fragment
situated 187-nt upstream of the 50 splice site of Bcl-xS is
targeted by staurosporine to stimulate Bcl-xS produc-
tion (38), likely through the PKC pathway (38); details of
the regulatory element remain to be unveiled. Ceramide
reduces the Bcl-xL product through two other elements
(CRCE1 and CRCE2) and SAP155 (36,42,43), and protein
phosphatase 1 (PP1) (36). Sam68 controls Bcl-x splicing as
well but the target pre-mRNA element is unknown (44).
There are also elements in the Bcl-xL downstream intron
that are involved in the responses to cytokines and TPA
(37). Together, these ﬁndings indicate that multiple pre-
mRNA elements/factors are involved in the control of
Bcl-x splicing, as for mammalian genes in general (45,46).
G-tracts are splicing regulatory pre-mRNA elements.
The minimal binding and functional element is GGG and
two G-tracts with a variable spacer are stronger than one
copy in splicing and protein-binding assays (47–49). These
elements may play a role in intron deﬁnition where
the sequences they reside tend to be skipped as introns
(47,50). The elements can be either splicing enhancers or
silencers, by binding U1 snRNA (51), or members of the
hnRNP H family, including H1(H), H2 (H0), H3 (2H9),
F and GRSF-1 (41,48,49,52–55). Particularly, hnRNP H1
either enhances or represses the inclusion of target exons
(41,49,55–60).
In this report, we show that Ro controls the alternative
splicing of the endogenous Bcl-x gene by targeting a
G-tract element through an okadaic acid-sensitive path-
way. Similar G-tract element-containing exons of other
genes are regulated by Ro as well. Moreover, the G-tract
element appears to also mediate the control of alternative
splicing by other cell apoptotic inducers particularly
retinoic acid.
MATERIALS AND METHODS
Construction of splicing reporter plasmids
wDUP175 was derived from DUP175 (61,62), by replacing
the 30 splice site of the middle exon with a weaker sequence
(accaccctagccatctaatcacttatacacattcattttagC, with ‘C’ as
the ﬁrst nt of the downstream exon). For the RARG
minigene, the lengths of the upstream intron, exon and
downstream intron included in the insert are 125, 326
and 294nt, respectively. Mutations were made by poly-
merase chain reaction (PCR) using Pfu DNA polymerase.
Minigene inserts were between the ApaI and BglII sites
of DUP175, unless otherwise indicated, and conﬁrmed by
sequencing.
Cellculture, transfection and treatment
MDA-231 and BT20 cells were cultured in DMEM supple-
mented with 5% fetal bovine serum. HEK 293T cells were
cultured in DMEM with 10% newborn calf serum.
Transfections were carried out with Lipofectamine 2000
(Invitrogen) 24h after plating according to the supplier’s
protocol, in 12-well plates using 0.15 mg reporter plasmid.
Transfected cells were incubated with Ro for various time
intervals as indicated in the text and lyzed for RNA
extraction. Cells were treated in serum-free media. All
phosphatase and kinase inhibitors and other chemical
agents for cell treatment were purchased from Sigma–
Aldrich, Oakville, Ontario, Canada, except DMSO (Fisher
Sci., Ottawa, Ontario, Canada).
Semiquantitative reverse transcription (RT)-PCR
Total RNA was extracted with GenElute Mammalian
Total RNA Miniprep Kit (Sigma-Aldrich, Oakville,
Ontario, Canada). RT-PCR was carried out as previously
described (61), except 400ng RNA was used for 10 mlo f
reverse transcription reaction. PCR reaction was run at an
annealing temperature of 608C for 26 cycles. The products
were resolved in 3% agarose gels containing 0.5 ug/ml of
ethidium bromide in TBE buﬀer and documented on a UV
transilluminator under a digital camera. Band intensities
were quantiﬁed with the NIH Image J software 1.37v
(developed at the U.S. National Institutes of Health and
available on the Internet at http://rsb.info.nih.gov/ij/).
The percentages of exon-excluded or -included product
in agarose gels were calculated from the actual band
intensities relative to the total of spliced products
(excluding the cryptically spliced ones). Agarose gel
pictures in the ﬁgures are inverted digital images. The
percentages of exon-excluded or -included products of the
electropherograms, obtained in an automated workstation
(63), were calculated from their molar numbers.
Humangenome database search
Annotated human genome sequences (NCBI36) were
downloaded from the ENSEMBL website (http://www.
ensembl.org). A bioperl script EXON was written to
extract all the exons with up to 500nt ﬂanking intron
sequences into a whole-genome exon database. This
database was searched for exons containing the G-tract
element GGGGNNNNNNGGGG using another Bioperl
script ExonElement to yield a database of the G-tract-
containing exons in MS Excel. Exons with the same
sequences were ﬁltered out. The unique ENSEMBL gene
IDs were used to obtain the HGNC symbols (whichever
available) of each gene from Biomart (http://www.
biomart.org/). These symbols were used to identify genes
in the toxicity category with the Ingenuity Pathway
Analyses, a software application that allows identiﬁcation
of proteins/genes clustering in the same pathway/category
from a group of target genes (http://www.ingenuity.com).
Exons of genes in this category were obtained by ﬁltering
the MS Excel ﬁle with the HGNC symbols/ENSEMBL
Nucleic Acids Research, 2008, Vol. 36, No. 10 3321gene IDs. The alternative exons were identiﬁed by aligning
the exon/intron sequences using the UCSC genome
database (http://www.genome.ucsc.edu/).
RESULTS
Rodecreases theproportion of theBcl-xL product
In examining the alternative splicing of the Bcl-x gene
by extracellular factors, we found that Ro decreased
the proportion of the Bcl-xL product in the human
breast cancer cell lines MDA-231 and BT20 (Figure 1).
In these cells, Bcl-xL was the predominant isoform (98%)
and Bcl-xS was barely visible without treatment. Upon
addition of Ro, the proportion of the Bcl-xL variant
started to decrease at 6h and was reduced about 15%
at 22h in MDA-231 cells and 10% at 28h in BT20
cells. Similar reductions by Ro were also observed in PC12
and HEK293T cells (data not shown, and see below).
Therefore, Ro decreases the proportion of the Bcl-xL
product.
A16-nt G-tract element mediates Roregulation
ofBcl-x splicing
To identify the pre-mRNA sequence that can mediate
the Ro eﬀect on the reduction of the Bcl-xL product,
we cloned Bcl-x fragments containing partial Bcl-x exon 2
and diﬀerent lengths of the downstream intron into a
splicing reporter derived from the human b-globin gene
(61,62). Splicing changes of these reporters were examined
by RT-PCR after transfection into HEK293T cells
followed by incubation with or without Ro. The result
showed that inclusion of the middle exon of the control
reporter (DUP175) was not changed by Ro (Figure 2A,
lanes 1 and 2). In contrast, inclusion of the Bcl-xL exon in
the Bcl-x11 construct was reduced by Ro (lanes 3 and 4,
12% reduction). The Ro eﬀect became stronger when
the downstream intron was shortened in Bcl-x12 (lanes 5
and 6). Therefore, the Bcl-x12 insert is suﬃcient to mediate
Ro-induced Bcl-xL reduction. Since the control and Bcl-x
mini-genes have the same promoter, 30 polyadenylation
sites and ﬂanking exons, the diﬀerence in their responses
to Ro is likely due to their diﬀerences in the middle exon
and ﬂanking introns, suggesting that the Bcl-x inserts
harbor RNA elements responsive to Ro-induced reduc-
tion of Bcl-xL.
We then went on scanning this insert for RNA elements
essential for the observed Ro eﬀect. Series deletions (30-nt
each) were made from the 50 end Bcl-x sequence of a
Bcl-x12 insert (wBcl-x12––x18, Figure 2B). Similar tests
of these reporters in HEK293T cells showed that the
Ro-induced exon exclusion disappeared completely start-
ing from wBcl-x14 (lane 6). Replacing the 30-nt element
deleted from wBcl-x13 with a b-globin sequence abolished
the Ro eﬀect as well (data not shown). These observa-
tions suggest that a sequence speciﬁcally essential for
the Ro eﬀect on splicing is within the 30-nt element,
which contains the G-tracts shown to reduce the Bcl-xL
product (41).
It should be noted that the wBcl-x13 also lost a substan-
tial amount of Ro eﬀect compared to Bcl-x12 (compare
lanes 2 and 4), suggesting that the 30-nt fragment deleted
from wBcl-x12 is also essential for the Ro eﬀect. However,
mutating the competing 50 splice site in this fragment
completely abolished the Ro eﬀect (data not shown),
indicating that the eﬀect from this fragment is mainly due
to the competing 50 splice site. Therefore, instead of the
competing 50 splice site, we focused on the fragment con-
taining the G-tracts for Ro-targeted regulatory elements.
To see whether the G-tract region is essential for the Ro
eﬀect in the context of alternative 50 splicing of Bcl-x, we
made construct Bcl-x20 and its G-tract region mutant
(Figure 2C). This wild-type construct produces mainly
Bcl-xL (72%), similarly as the endogenous Bcl-x gene, and
responded to Ro treatment with a reduced percentage of
Bcl-xL (57%) when expressed in HEK293T cells (15%
reduction, lanes 1 and 2). The mutation led to almost
all Bcl-xL product (lane 3), similarly to the reported
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Figure 1. Ro decreases the proportion of the Bcl-xL product. (A) Agarose gels of the RT-PCR products of Bcl-x from RNA samples of MDA-231
(upper) or BT20 (lower) cells incubated with Ro for diﬀerent time intervals, with Bcl-x splicing patterns indicated to the left. (B) A graphed time
course of the net changes of the percentages of the Bcl-xL product relative to the starting time (0h), in MDA-231 (squares) or BT20 (triangles) cells.
The dotted line marks the starting baseline level of the Bcl-xL product in the NT samples of each cell line. The ﬁnal concentration of Ro was 2mg/ml.
Ro, Ro-31-8220; NT, nontreated, control for Ro, which was dissolved in DMEM.
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Ro (lane 4). These data suggest that the G-tract region is
essential for Ro-induced reduction of the Bcl-xL product
in Bcl-x’s alternative 50 splicing context.
To isolate the G-tracts’ eﬀect on exon inclusion in a
completely heterologous context, we transferred 21nt of
the G-tract fragment (Gt21) into the wDUP175 middle
exon or its ﬂanking introns (Figure 3). Replacements of
exon sequences with the Gt21at various positions lead
to complete exon exclusion (Figure 3A, lanes 2–7),
while Gt21 insertion or replacement mutations in introns
did not substantially change the splicing pattern (lanes 8
and 9). Therefore, the Gt21 appears to be an exonic
silencer in this context.
To identify a shorter sequence suﬃcient for the silencer
activity, the G tetrads in the Gt21 were mutated in the
B
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Figure 2. A G-tract region in Bcl-x is essential for the Ro-induced reduction of the Bcl-xL product. (A) (Upper) Diagram of the control splicing
reporter DUP175 and cloned inserts of the Bcl-x minigene splicing reporters. Boxes represent exons and lines introns. Black boxes represent the Bcl-
xL exon and black heavy lines Bcl-x intron. In the Bcl-x constructs, 51-nt b-globin exon sequence was fused with the exon 2 of Bcl-x containing 20-nt
Bcl-xS, the 189-nt Bcl-xL exons and diﬀerent lengths (nt) of the downstream introns as indicated. ApaI and BglII are the cloning sites. The arrows
indicate locations of PCR primers. (Bottom) An agarosel gel of RT-PCR products from HEK293T cells transfected with the splicing reporters (as
indicated above the gel) and treated with Ro or without (NT). The spliced products are diagramed to the right of the gel. Gel representative of at
least three samples for each lane. (B) (Upper) Bcl-x sequence included in wBcl-x12 and other reporters. Exon sequences are in upper cases and intron
in lower cases. The vertical line marks the 50 splice site exon–intron junction for Bcl-xS. The starts of the arrow lines indicate the Bcl-x insert starting
positions in each splicing reporter minigene (with reporter numbers below the arrows). In these wBcl-x reporters, the upstream 30 splice site of the
middle exons was replaced with a weaker sequence (see Materials and methods section) for a stronger Ro eﬀect. (Bottom) Similar to the gels in (A)
except with diﬀerent splicing reporters as indicated above the gel. The 21-nt G-tract region (Gt21) to be examined and the CRCE2 sequence required
for ceramide-regulation of Bcl-x splicing is underlined. (C) Role of the G-tract region in Ro-induced Bcl-xL reduction in its alternative 50 splicing
context. (Upper) Diagram of the Bcl-x20 splicing reporter with the Bcl-x exon 2 (black box, including the 189-nt Bcl-xL sequence) and downstream
intron (514nt, heavy line) cloned between the Nsi I and Bgl II sites of DUP175. The splicing patterns and the wild-type and mutant (mutated nts
underlined) sequences of the G-tract region are as indicated. Arrows: locations of PCR primers. (Lower) An agarose gel of the RT-PCR products
from cells transfected with the splicing reporters without treatment (NT) or treated with Ro (Ro) as indicated above the gel, with molecular size
markers to the left and splicing products (sizes) to the right. Cells were treated with 2mg/ml Ro or nontreated (NT) for overnight.
 Product from
cryptic 30 splice site as indicated to the right of the gels or the cryptic splice position in the sequence. Gel representative of two experiments; open
triangle, product resulted from pre-mRNA or plasmid; M, molecular size marker (bp).
Nucleic Acids Research, 2008, Vol. 36, No. 10 3323reporter 144 (Figure 3B). Mutation of each G tetrad
barely relieved the repression (96 and 94% exon exclusion,
lanes 3 and 4, respectively, compare with 99% for lane 2).
In contrast, simultaneous mutations of both G tetrads
abolished the repression, reducing the exon exclusion to a
level similar to the vector’s (65% exon exclusion, lane 5,
compare with 60% for lane 1). Mutation in the spacer
between the G tetrads did not change the repression
(SPr, lane 6). Moreover, replacing the b-globin sequence
with only 16nt encompassing both G tetrads (Gt16) led to
complete repression (lane 7). Therefore, the Gt16, includ-
ing two G tetrads and a variable 6-nt spacer, is a minimal
sequence for the silencer activity in this reporter.
To examine the role of the G tetrads in Bcl-x response
to Ro, we mutated them to TCGA in the reporter
Bcl-x20 and tested the Ro eﬀect (Figure 4, left panel).
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Figure 4. The 16-nt G-tract element ‘TGGGGTAAACTGGGGT’ is essential for Bcl-xL and suﬃcient for a heterologous exon to be repressed by
Ro. Shown are agrose gels of RT-PCR products of HEK293T cells transfected with splicing reporter minigenes with the element sequences and
splicing patterns indicated above the gels. Bar graphs of the average percent ( SD, n=3) exon exclusion for each sample are below the gels. The
dotted horizontal lines mark the exon exclusion levels of the vectors. Cells were treated with 2mg/ml Ro or nontreated (NT) for overnight.
 A cryptic
50 splice product with 38-nt deletion at the 30 end of the middle exon (as indicated by the dotted line in the diagram above the gel);
  likely heteroduplex formed between the two splice variant products; open triangle, same as in Figure 2.
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Figure 3. The G-tract element is an exonic silencer. (A) (Upper) Diagram of Gt21 inserted into (arrowhead) or replaced (short horizontal lines)
vector sequences at the indicated positions in or ﬂanking the wDUP175 middle exon. The exonic position numbers indicate the 50 ﬁrst nt of the
element, counted from the ﬁrst nt of the exon. The intronic positions are relative to the last (upstream, UI) or ﬁrst (downstream, DI) nt of the intron.
(Bottom) An agarose gel of RT-PCR products of HEK293T cells transfected with the splicing reporters as indicated above the gel. (B) (Upper)
Diagram of the splicing reporters with mutations within the Gt21 reporter 144 as in (A). Bcl-x G-tract and mutant (underlined) sequences are aligned
under the replaced b-globin sequence (top, in the exon). (Bottom) Similar to that in (A) except for diﬀerent reporters as indicated above the gel. Vec,
wDUP175. Dotted lines refer to the weakened 30 splice site. Gels representative of two or three samples per lane. The exon-included or -excluded
products are indicated to the right of each gel. Percentages of exon-excluded products are below each lane.
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abolished the Ro-induced Bcl-xL exon exclusion (compare
lanes 3 and 4), as by the above mutation of the G-tract
region (Figure 2C). Therefore, the G-tract nucleotides
are essential for Ro-induced reduction of Bcl-xL in its
alternative 50 splicing context.
To see whether the Gt16 is suﬃcient to confer the Ro
eﬀect on a heterologous exon that by itself does not
respond to Ro, we transferred the Gt16 or its mutant to
the DUP175 (Figure 4, lanes 5–10). Inclusion of the Gt16
reporter exon was reduced 27% by Ro, compared to the
nontreated sample [lanes 7 and 8; the cryptic 50 splice
product has 38-nt deletion at the 30 end of the middle
exon, as described previously (64,65)]. This reduction
was almost abolished by the Gt16 mutation (lanes 9
and 10), suggesting that the Ro-induced exon exclusion is
indeed through the Gt16 element. Thus, the Gt16 is a
Ro-responsive RNA element.
To examine the role of the Gt16 in Ro-induced
alternative 50 splice site usage as in Bcl-x, we constructed
an alternative 50 splice site reporter DUP175AS. In this
reporter (Figure 4, right, lanes 11–16), the DUP175 ﬁrst
exon and its downstream 50 splice site was fused with
165-nt 30 half of the middle exon to form two identical
competing 50 splice sites. The Gt16 or its mutant sequence
was transferred in between the two 50 splice sites where
they were 28nt away from the upstream 50 splice site. Test
of these reporters showed that inclusion of the vector exon
was slightly reduced by Ro (14% reduction, lanes 11 and
12). In contrast, inclusion of the Gt16 reporter exon was
much more strongly reduced (34% reduction, lanes 13 and
14). Mutation of the Gt16 led to higher basal level exon
exclusion (37%, lane 15) than the Gt16 reporter in
nontreated cells. This higher level of the exon-excluded
product was not further increased upon Ro treatment
(compare lane 16 with lane 15, P=0.31). Therefore,
despite its promoting eﬀect on the exon-excluded product,
the mutant sequence does not mediate the Ro eﬀect for
further exon exclusion. The Gt16 element is thus indis-
pensable for the strong Ro eﬀect on the alternative 50
splice site usage (Figure 1).
Taken together, the data from the three reporters (in
Figure 4) suggest that the Gt16 element is essential and
suﬃcient to mediate Ro-induced exclusion of both the
cassette and the alternative 50 splice exons.
The Ro-regulation ofalternative splicing through
the G-tractelement requires phosphatases
To examine the signaling pathway essential for the
Ro-regulated splicing, we tested the eﬀects of chemicals
related to Ro targeted pathways (Figure 5). TPA, a PKC
stimulator (66), did not change the splicing pattern of the
DUP175AS-Gt16 reporter in HEK 293T cells (Figure 5A,
lane 3), although it did have eﬀect on Bcl-xL produc-
tion in control PC12 cells (data not shown). Adding TPA
after Ro to the HEK 293T cells slightly reduced the Ro
eﬀect (lane 4, compared to lane 6), suggesting the involve-
ment of PKC to some extent. In contrast, okadaic acid,
a phosphatase inhibitor (67), reduced the Ro-induced
exon exclusion in a concentration-dependent manner
(lanes 7–10), with almost complete inhibition of the
Ro eﬀect at 1000nM. These observations suggest that
okadaic acid inhibits the Ro-regulated alternative splicing
throughthe G-tract element. Sinceboth low (<50 nM) and
high ( 100 nM) concentrations of okadaic acid diﬀeren-
tially inhibit the Ro eﬀect, it is likely that both phos-
phatases 2A and PP1 are involved in the Ro regulation of
splicing through the Gt16 element in HEK293T cells.
Similar Ro eﬀects were observed for the endogenous
Bcl-x gene in these same samples (Figure 5B). Therefore,
the phosphatases PP2A and PP1 are likely essential for the
Ro-regulation of splicing of both the Gt16 reporter and
the endogenous Bcl-x genes.
The G-tractelement isalso critical for Ro-regulation
ofalternative splicing ofother genes
To see whether inclusion of similar G-tract-containing
exons of endogenous genes can also be regulated by Ro,
we ﬁrst searched the human genome for exons containing
the G-tract element GGGGNNNNNNGGGG, where
the spacer Ns are nonessential for the silencer activity
(Figure 3) and variable for both protein binding and
splicing activities (47,49). This search identiﬁed 3374 exons
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Nucleic Acids Research, 2008, Vol. 36, No. 10 3325of 2707 genes. Of these, we examined by RT-PCR 46
middle exons of genes in the Toxicity category as described
by Ingenuity (http://www.ingenuity.com), with RNA sam-
ples of MDA-231 cells treated with or without Ro. We
noticed that a group of genes, particularly Bcl-x, LCAT
and ALAS1 (Figure 6A), responded with either decreased
or increased percentages of exon-excluded product upon
Ro treatment. This data suggest that a group of similar
G-tract-containing exons are regulated by Ro.
To see whether the G-tracts in these exons are involved
in the Ro-regulation of alternative splicing as in Bcl-xL,
we then tested the Ro eﬀect on three alternative exons in
splicing reporters and found that the RARG (retinoic
acid receptor, gamma) was responsive to Ro (Figure 6B),
as well as a NOL1 (nucleolar protein 1) exon (data not
shown). The RARG exon was completely included in cells
without treatment (lane 3). Ro treatment induced exon
skipping (13% exclusion, lane 4). Mutation of the G-tract
element doubled the exon skipping (26% exclusion,
lane 6). Therefore, the presence of the G-tract element
of the RARG exon reduces the Ro-induced exon exclu-
sion, unlike that in the Bcl-xL exon (see Discussion
section), a context-dependent eﬀect of regulatory RNA
elements also seen in other systems (68,69). Nonetheless,
this indicates that the G-tract elements are also involved in
the Ro-regulated alternative splicing of other genes.
The G-tractelement also mediates other apoptotic
agents-induced alternative splicing
To see whether the G-tract element also mediates other
stimuli to regulate splicing, we used the reporter
DUP175AS-Gt16 to screen a number of chemicals related
to cell cycle or cell death for splicing changes (Figure 7A).
Of these chemicals, roscovitine (a cyclin-dependent
kinase inhibitor), U0126 (a MEK1/2 inhibitor) and
13-cis-retinoic acid (RA) increased at least 1.5-fold of the
percent exclusion of the reporter alternative exon (#11, 13
and 14), relative to the nontreated control samples.
Interestingly, for the endogenous Bcl-x of the same
samples, roscovitine and RA also showed similar eﬀect
(#11 and 15), as well as others including nocodazol (an
inhibitor of microtubule formation), SB202190 (a p38
MAPK inhibitor) and SP600125 (a JNK inhibitor) (#5,
9 and 12). Therefore, of the multiple chemicals that modu-
late the Gt16 reporter and/or endogenous Bcl-x splicing,
roscovitine and RA induced at least 1.5-fold changes in
both the reporter and endogenous Bcl-x.
To further examine the RA eﬀect, various concentra-
tions of RA were applied to cells expressing the Gt16
reporter or its mutant. The result showed RA dosage-
dependent increase of the percent exclusion of the
alternative exons in the reporter (Figure 7B, lanes 1–10).
Moreover, this regulation was not seen in the Gt16 mutant
(lanes 9 and 10). Therefore, the G-tract also mediates RA
regulation of splicing.
DISCUSSION
Alternative splicing of genes in cell growth/death has been
examined in several cases but the control of these genes by
external factors, particularly those inducing cell apoptosis,
has just started to be analyzed (36–38,42,43). Our data
here support a role for the G-tract element in mediating
the regulation of alternative splicing of a group of genes
by Ro and other apoptosis-inducers particularly RA.
B
RARG: GGGGCACTCAGGGG 
RARGm:TCAGCATGACTCTC
Vec RARG Splicing reporter
NT Ro NT Ro NT Ro Treatment
M
404
242
563
190
147
0
10
20
30
123456
%
 
E
x
o
n
e
x
c
l
u
s
i
o
n
lanes
bp
Bcl-x LCAT M
15
100
300
500
700
1100
bp
336
147
38 64
7.2 5.5
36
% exon exclusion
s.d.
Net  % change
− + −− ++
bp
A
380
155
0
0
17
7
17
bp
−13
354
189
bp
ALAS1
27
3.1
14
6.4
RARGm
Figure 6. Ro-regulation of other G-tract-containing exons. (A) Electropherograms from an automated workstation of RT-PCR products of the
G-tract-containing genes from RNA samples of MDA-231 cells treated without (–) or with (+) Ro (2mg/ml) for 22h. Indicated above the
electropherograms are the respective gene names, below are the average percentages ( SD, n 3) of the molar amount of exon-excluded products
and the net changes for each gene after Ro treatment, and to the right are the sizes (bp) of the PCR products. Molecular size (bp) markers (M) are
aligned on the right side. LCAT: lecithin-cholesterol acyltransferase; ALAS1: aminolevulinate, delta-, synthase 1. (B) Agarose gels of RT-PCR assay
showing the splicing changes of the reporters as indicated above the gels. RARG, retinoic acid receptor, gamma; Vec, DUP175. Below the gel is a
bar graph of the average percentages (  SD, n=3) of exon-excluded products of each lane. The dotted line marks the exon exclusion levels of the
G-tract wild-type reporters induced by Ro.
3326 Nucleic Acids Research, 2008, Vol. 36, No. 10G-tracts inintron definition and Ro-induced
alternative splicing
In the Gt16 element, besides the two G tetrads, there are
also two Ts on the two ends and six variable spacer
nucleotides (Figures 3 and 4). The spacer is not essential
for the silencer activity (Figure 3B, lane 6). Earlier studies
with G-tracts indicate that two G triplets with 2–4nt
variable spacer nucleotides regulate alternative splicing
(47). Consistently, the G nucleotide mutations (Figure 4,
left panel) in the Gt16 are essential for the constitutive as
well as Ro-induced repression of Bcl-xL production.
Pre-mRNA sequence regions containing G 3 elements
tend to be skipped as introns accompanying the activation
of the upstream 50 or downstream 30 splice sites and the
G-tract elements are proposed to play a role in intron
deﬁnition (47,55,70). These elements are enriched close
to intron ends in the genome (47,50). It is proposed
that binding of these elements by hnRNP proteins may
bring two splice sites in closer proximity to stimulate
splicing (50). It is also enriched in pseudoexons as splicing
silencers (60). Presently, the identiﬁed G-tract splicing
enhancers are mostly in introns (55–57), except in one case
(58), and silencers in exons or pseudo exons (59,60,70,71).
In our experiments, when the Gt16 is put in-between
two identical alternative 50 splice sites, usage of the
upstream 50 splice site was increased (Figure 4, lanes 11
and 13), consistent with similar previous observations for
G-tracts and other exonic splicing silencers (47,70). When
the G-tract element from Bcl-x is placed in wDUP175,
the middle exon is completely excluded (Figure 3). These
are consistent with the notion that G-tracts signify the
sequence they reside as introns.
These experiments also support the G-tract element as
a Ro-responsive RNA element in inducible alternative
splicing, as shown by mutations of the G-tract element in
Bcl-x and other alternative exons as well as in heterologous
contexts (Figures 2, 4 and 6). Ro treatment decreases the
inclusion of both cassette and alternative 50 splice exons
that contain G-tract elements. For the competing 50 splice
sites in Bcl-x and the DUP175AS-Gt16 reporter, it remains
to be determined whether Ro acts by inhibiting the
constitutive splicing factors for the downstream or
promoting them for the upstream 50 splice site.
The eﬀect of the G-tract element on Ro-regulated splic-
ing shows context-dependence. In the Bcl-x and DUP175-
Gt16 and DUP175AS-Gt16 reporters, mutation of the
Gt16 reduced or abolished the Ro eﬀect (Figure 4);
however, mutating the G-tract in the RARG reporter, to
the same sequence as in the Bcl-x12 mutant that abolished
the Ro eﬀect (data not shown), instead enhanced the
Ro eﬀect (Figure 6B). Moreover, inclusion of the middle
exon of the RARG mini-gene is repressed in HEK293T
cells but its endogenous exon appears enhanced in MDA-
231 cells by Ro (Figure 6, and data not shown). These
diﬀerent eﬀects likely reﬂect the complexity of the control
of alternative splicing by multiple elements/factors
depending on the diﬀerent sequence contexts around the
regulatory element or on diﬀerent splicing factors in
the cell lines. Similar context-dependent eﬀects on splic-
ing by a regulatory element or a stimulus have also
been observed in other cases of alternative splicing
(14,68,69,72–75).
From other studies, it is clear that multiple pre-mRNA
elements can be present in the same exon to respond
to external stimuli. For example, the NMDAR1 exon 21
contains two CaRRE elements and several UAGG motifs
that respond to membrane depolarization and CaMK IV
(76,77). In addition to the Ro-targeted Gt16 element,
there are also several other elements responsive or
involved in the regulation of Bcl-x by external stimuli.
The TPA- and Ro-regulated splicing is aﬀected by ele-
ments in the Bcl-xL downstream intron (37) (Figure 2).
The staurosporine-targeted element in Bcl-x lies in a
361-nt fragment 187-nt upstream of the Bcl-xS 50 splice
site. Ceramide requires another two elements CRCE1 and
CRCE2 located upstream the Bcl-xS 50 splice site and
downstream the Gt16 element, respectively. The pyrimi-
dine-rich CRCE2 element essential for the ceramide eﬀect
was left intact in the wBcl-x14 construct (Figure 2B), but
this construct does not respond to Ro, suggesting that
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In contrast, the G-tract element itself is suﬃcient to do
so (Figure 4), supporting a speciﬁc role for the Gt16 in
responses to Ro. The relationship among these diﬀerent
elements in responses to the diﬀerent external stimuli
remains to be examined.
Factors between theapoptotic agents and the G-tract
element inthe inducible alternative splicing
Ro inhibits PKC and the expression of the MAPK phos-
phatase 1 (23,24). It also activates the JNK protein kinase
(24). The PKC stimulator TPA itself did not change the
splicing of the Gt16 reporter and only slightly reduced the
eﬀect of Ro on the Gt16 reporter in HEK293T cells
(Figure 5, lanes 3 and 4). The Ro eﬀect on the reporter is
not sensitive to the JNK inhibitor SP600125 in HEK 293T
cells (data not shown). In contrast, the Ro eﬀect was
inhibited by okadaic acid in a concentration-dependent
way (Figure 5). It is thus likely that the Ro-regulation of
alternative splicing through the G-tract element involves
both PP2A and PP1 (67), protein phosphatases essential
for splicing (78–81), and particularly PP1 is required for
ceramide-induced Bcl-x splicing (36). Since the phospha-
tases can modulate a variety of protein kinases including
PKC (82), further detailed investigation is necessary to see
whether the phosphatases act with PKC or other protein
kinases in the Ro-regulated splicing.
In addition to Ro, the G-tract element is also targeted
by other apoptotic inducers particularly RA to control
splicing (Figure 7). RA targets its nuclear steroid receptor
to control gene transcription (83,84). Interestingly, co-ac-
tivators of nuclear steroid receptors are known to be
involved in the control of alternative splicing (85–89).
G-tract elements can directly interact with the U1
snRNA to promote the usage of the upstream 50 splice site
(51). They can also bind several members of the hnRNP H
family to regulate splicing (41,48,49,52–55), particularly of
the Bcl-x gene. HnRNP H family members are diﬀeren-
tially expressed among tissues or in cancer cells (90,91),
and hnRNP H1 is phosphorylated in tumor cells upon
retinoic acid treatment (92). We also observed hnRNP
H1/F binding to the G-tracts of the RARG exon in assays
using UV crosslinking-immunoprecipitation with an anti-
hnRNP H1/F antibody, and increased hnRNP H1/F
phosphorylation by okadaic acid in in vivo
32P-labeling
assays (data not shown), implying the involvement of
hnRNP H1/F in the Ro-regulated splicing. However, since
most of the hnRNP H family members are around 50kDa,
the possibility of the binding by the other members to the
G-tract in UV crosslinking cannot be ruled out yet before
individual members are examined and followed by loss-of-
function studies.
Impactof theregulation of splicing by apoptotic agents
oncell growth/death
Several apoptotic agents induce alternative splicing of
genes in cell growth/death (36,38). Particularly interesting
is that the Bcl-x product is switched by TPA to Bcl-xL
(37), which promotes cell growth, and by Ro, ceramide
and staurosporine to Bcl-xS (36,38), which promotes cell
death. These changes appear consistent with the inducer
eﬀects on cell growth/death.
Of the other G-tract element-containing genes that are
also responsive to Ro regulation of their exon inclusion
(Figure 6), RARG is involved in the retinoic acid signaling
and cell death. Taken together with the role of Bcl-x in cell
growth/death, it is likely that Ro regulation of these exons
will impact on a group of genes involved in cell growth/
death.
The eﬀect of the alternatively spliced variants on gene
function is exempliﬁed in the RARG gene. The G-tract-
containing alternative exon of RARG encodes a segment
of the NH2 terminal of the receptor. This region is
phosphorylated by the JNK and CDK7 kinases in RARG
or its family members (93–97), and is critical for tran-
scriptional activities (83). Therefore, changing the inclu-
sion level of this exon by Ro probably aﬀects the
phosphorylation and transcriptional activities of RARG.
Another potential target of G-tract-mediated regulation
is deltap53, a splice variant of p53 with one exon skipped
(98). Deltap53, but not p53, trans-activates the Cdk
inhibitor p21 in S-phase attenuation (98). Interestingly,
the alternative exon contains three G-tracts.
Taken together with the functions of the G-tract-
containing exons and the apoptotic agents on cell death,
it is likely that the G-tract elements play a role in
controlling the generation of cell death-promoting pro-
ducts (e.g. Bcl-xS) through alternative splicing. More
intensive analysis with whole-genome microarrays will
allow us to see whether these changes are part of the
program contributing to cell apoptosis induced by these
agents.
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